-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although balancing the effects of treatment and the risk of complications is essential for elderly patients with aggressive non-Hodgkin's lymphoma (NHL), few studies have described the clinical outcomes, toxicity rates, and utilization of healthcare in these patients
.
Therefore, a research team from the United States conducted a retrospective study to evaluate the clinical characteristics, prognosis, treatment toxicity, unplanned hospitalization rate, and ICU hospitalization in patients with aggressive non-Hodgkin lymphoma (NHL) aged 65 years or older.
Although balancing the effects of treatment and the risk of complications is essential for elderly patients with aggressive non-Hodgkin's lymphoma (NHL), few studies have described the clinical outcomes, toxicity rates, and utilization of healthcare in these patients
The study included 295 patients with a median age of 73 years (range 65-100 years); 96/295 or 32.
5% of patients were between 65 and 69 years old; 77/295 or 26.
1% of patients were 70- 74 years old; 59/295 (20.
0%) patients were 75-79 years old; 63/295 (21.
4%) patients were over 80 years old
.
Most patients received CHOP treatment (194/295, 65.
The study included 295 patients with a median age of 73 years (range 65-100 years); 96/295 or 32.
Treatment and prognosis
Treatment and prognosisThe ORR of the total population was 86.
9% (253/291), and the complete remission (CR) rate was 84.
2% (245/291)
.
The median follow-up time was 5.
The ORR of the total population was 86.
After treatment, the incidence of grade 3-5 non-hematological toxicity was 42.
3-5 levels of toxicity related factors
3-5 levels of toxicity related factorsAmong patients aged 65-69, 70-74, 75-79, and 80 years old, the 5-year OS rate was 82.
2% (95%CI, 72.
4 -88.
7) and 72.
0% (95%CI, 59.
7 -81.
1), 73.
6% (95% CI, 59.
2-83.
6) and 66.
4% (95% CI, 52.
5-77.
0)
.
Grade 3-5 non-hematological toxicity is 35.
Among patients aged 65-69, 70-74, 75-79, and 80 years old, the 5-year OS rate was 82.
In the multivariate model (n = 286), hypoalbuminemia (OR, 4.
Factors related to unplanned hospitalization
Factors related to unplanned hospitalization Factors related to unplanned hospitalizationIn the multivariate model (n = 286), hypoalbuminemia (OR, 2.
83; 95% CI, 1.
43-5.
58; p = 0.
003), high comorbidity score (OR, 3.
93, 95% CI, 1.
82-8.
49) ;p = 0.
001), EPOCH with or without rituximab treatment regimen (OR, 5.
45; 95%CI, 1.
45-20.
5; P = 0.
012) is associated with a high rate of unplanned hospitalization in the first 6 months after starting treatment
.
83; 95% CI, 1.
43-5.
58; p = 0.
003), high comorbidity score (OR, 3.
93, 95% CI, 1.
82-8.
49) ;p = 0.
001), EPOCH with or without rituximab treatment regimen (OR, 5.
45; 95%CI, 1.
45-20.
5; P = 0.
012) is associated with a high rate of unplanned hospitalization in the first 6 months after starting treatment
.
In summary, most of the elderly aggressive non-Hodgkin's lymphoma (NHL) treatment survived for more than 5 years, and nearly half of the patients experienced toxicity and unplanned hospitalization
.
Therefore, it is necessary to strengthen clinical intervention for these patients
.
In summary, most of the elderly aggressive non-Hodgkin's lymphoma (NHL) treatment survived for more than 5 years, and nearly half of the patients experienced toxicity and unplanned hospitalization
.
Therefore, it is necessary to strengthen clinical intervention for these patients
.
Most elderly patients with aggressive non-Hodgkin's lymphoma (NHL) survive for more than 5 years, and nearly half of the patients experience toxicity and unplanned hospitalization
.
Therefore, it is necessary to strengthen clinical intervention for these patients
.
Most elderly patients with aggressive non-Hodgkin's lymphoma (NHL) survive for more than 5 years, and nearly half of the patients experience toxicity and unplanned hospitalization
.
Therefore, it is necessary to strengthen clinical intervention for these patients
.
Original source:
Original source:Johnson PC, Yi A, Horick N,et al.
Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
Oncologist.
2021 Jul 29.
doi: 10.
1002/onco.
13915.
Epub ahead of print .
PMID: 34327767.
Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
Oncologist.
2021 Jul 29.
doi: 10.
1002/onco.
13915.
Epub ahead of print .
PMID: 34327767.
Leave a message here